Free Newsletter
J&J suits get 'mass' status in Vioxx court
The New Jersey Supreme Court deemed litigation over Johnson & Johnson's antibiotic Levaquin as a mass tort, which is expected to encompass thousands of cases. The lawsuits allege that Levaquin caused Achilles' tendon ruptures and other tendon damage. The kicker: the litigation will be heard in the court of Judge Carol Higbee, in Atlantic County. The same court that hosted the infamous $4.85 billion Vioxx settlement.
J&J had argued for Middlesex County, which is closer to its HQ. But in petitioning for Higbee's court, plaintiff's lawyer Michael London argued that her experience with high-volume liability cases--such as Vioxx--would help in the Levaquin litigaton.
The FDA asked J&J and other drugmakers to add warnings of tendon damage and rupture to Levaquin and its sister meds in the fluoroquinolone class. That was in 2008. Levaquin had been approved since 1996, however. In addition to London's six Levaquin suits, Lanier Law Firm--also of Vioxx fame--and a New York firm have sued J&J over the drug in New Jersey. In his petition, London said that "other national firms" also expect to sue in the state.
- read the New Jersey Law Journal story
- check out the post at BNet Pharma
Related Article:
FDA orders warning for antibiotic class
Comments
Dose anyone remember the Vioxx Case in TX. Where the women was awarded 256 Million Dollars, by a jury, it was in her favor of 10 to 2. I need the date of that case, and the name of the attorney that represented that Vioxx case in TX.
If you could help me I would appreciate it very much.
Thank You.
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





